About

Tango Therapeutics is developing novel cancer medicines using DNA sequencing and CRISPR-based target discovery to create breakthrough therapies that target specific tumor vulnerabilities, including loss of tumor suppressor gene function, multiple oncogenic drivers, and immune evasion, leveraging the principle of synthetic lethality. The company's approach focuses on expanding the reach of genetically targeted therapies to take direct aim at specific tumors.